Dr. John Fortuna Announces Healthcare Grant Challenging Students to Redefine Aging through Innovation in Longevity and Regenerative Medicine
Dr. John Fortuna
CLEVELAND, May 29, 2025 (GLOBE NEWSWIRE) -- The Dr. John Fortuna Grant, founded by Cleveland-based chiropractor and wellness advocate Dr. John Fortuna, is now accepting applications for the 2026 cycle. This nationwide academic grant invites eligible healthcare students to present visionary ideas about the future of aging, longevity, and regenerative medicine—an initiative that aligns with Dr. John Fortuna's lifelong dedication to health, prevention, and sustainable wellness.
Open to undergraduate and graduate students across the United States, the Dr. John Fortuna Grant seeks to recognize and support those who demonstrate academic excellence and a commitment to evolving healthcare to enhance longevity and vitality for aging populations. As life expectancy increases, the quality of those additional years is a critical focus in medical discourse, particularly through advancements in regenerative medicine. Dr. John Fortuna sees this grant as a catalyst for encouraging young minds to address this challenge with innovative solutions.
Dr. John Fortuna has built a respected reputation as a thought leader in integrative healthcare. A graduate of Cleveland State University and Life University College of Chiropractic, Dr. John Fortuna has spent decades helping individuals achieve healthier, more active lives. His experience includes leadership in multidisciplinary health clinics, hands-on patient care, and participation in international medical missions. Now, with the Dr. John Fortuna Grant, he is creating a platform for students to share transformative visions for longevity and regenerative medicine in healthcare.
Eligibility Criteria
To apply for the Dr. John Fortuna Grant, students must:
Be enrolled in an accredited undergraduate or graduate healthcare-related program.
Maintain a minimum GPA of 3.0.
Demonstrate financial need.
Submit an original essay between 500–1000 words in response to the following prompt:'Imagine a world where 100 is the new 60: How can healthcare, through innovations in longevity and regenerative medicine, evolve to make aging a journey of strength, not decline? Share your vision for medicine that extends vitality, not just years.'
In addition to the essay, applicants must provide:
An unofficial academic transcript
A one-page resume or CV
One letter of recommendation from a faculty member or mentor
All application materials must be submitted via email to apply@drjohnfortunagrant.com by February 15, 2026.
This initiative not only provides financial assistance but also recognizes students capable of introducing practical and innovative solutions to enhance longevity through regenerative medicine. Dr. John Fortuna believes today's students will lead tomorrow's healthcare revolutions, particularly in the field of regenerative medicine—and this grant spotlights those with the talent and vision to do so.
The Dr. John Fortuna Grant is open to students from any U.S. city or state. What matters most is the applicant's ability to think critically, creatively, and compassionately about the evolving role of healthcare in promoting longevity and vitality through regenerative medicine.
With this program, Dr. John Fortuna continues his mission to promote holistic, preventive, and patient-centered healthcare. The grant affirms his belief that longevity should be matched by vitality, and that the future of regenerative medicine depends on those who dare to think differently.
To learn more about the Dr. John Fortuna Grant and how to apply, please visit: www.drjohnfortunagrant.com
Contact Info:
Spokesperson: Dr. John Fortuna
Organization: Dr. John Fortuna Grant
Website: https://drjohnfortunagrant.com
Email: apply@drjohnfortunagrant.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cb1e8831-337d-435c-b7bf-433948c0544d
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
an hour ago
- UPI
NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. File Photo by Annabelle Gordon/UPI | License Photo June 21 (UPI) -- The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. The NIH Office of AIDS Research or OAR told its employees this week it intends to phase out the guidelines by next June, the Washington Post reported, citing an internal staff email. According to the office, OAR "coordinates HIV/AIDS research across the National Institutes of Health and provides the largest public investment in HIV/AIDS research globally." "In the climate of budget decreases and revised priorities, OAR is beginning to explore options to transfer management of the guidelines to another agency within" the letter obtained by The Post reads. The OAR guidelines contain guidelines related to diagnosis and treatments of HIV and AIDS. There are currently more than 1 million people living with HIV in the United States. It was not immediately clear what the other agency referred to in the letter was or how such a move may affect the guideline, the Post reported. The news comes as President Donald Trump and Secretary of State Marco Rubio move to cut over $8 billion from the U.S. Agency for International Development, USAID and merge it into the State Department. State Department officials say the move comes with the expectation that other countries will increase their roles in delivering aid around the world. An April report published in the Lancet medical journal found around half a million children globally could die from AIDS by 2030 if the United States cuts its global relief funding. Earlier this week, the U.S. Food and Drug Administration approved use of the HIV drug lenacapavir, which is produced by California-based biopharma firm Gilead Sciences under the name Yeztugo. "Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," Gilead Science Chairman and Chief Executive Officer Daniel O'Day said in a statement on the company's website
New York Post
4 hours ago
- New York Post
Dog's ashes among dozens to rocket into orbit this weekend
Bone voyage! A beloved dog named Franz will take his final leap this weekend — into Earth's orbit. The yellow labrador's ashes will be on board the inaugural Perseverance Flight from Texas-based Celestis Inc., which is scheduled to launch around 5:30 p.m. Sunday from Vandenberg Space Force Base in Santa Barbara, CA. 4 Franz was like a sibling to Elizabeth Moore before he died at age 13 in October 2020. Celestis, Inc Carrying a total of 166 titanium and aluminum capsules, each about a quarter to a half-inch in size and filled with DNA or cremated remains, the 23-foot-tall SpaceX Falcon 9 rocket will take two trips around Earth's low orbit at a mind-boggling 17,000 mph. The space flight will last about three hours before the rocket — still carrying its priceless payload — re-enters the atmosphere and lands in the Pacific Ocean somewhere between Alaska and Hawaii, according to Celestis CEO and co-founder Charles Chafer. A recovery ship, which was already out at sea Friday in anticipation of the launch, 'will track the incoming rocket, hopefully get a visual on it, and then go pick it up out of the ocean,' Chafer explained. 4 The Texas-based company Celestis Inc.'s inaugural Perseverance Flight will take two trips around Earth's Lower Orbit after blastoff on Sunday. The capsules will first be transported to Germany, then, within two months, distributed back to the families, who each paid a whopping $3,500 to send their loved one to the stars. While the price to send Franz on the voyage was 'a lot more' than the pooch itself, his owner, Harvin Moore, said with a laugh, it was only fitting for the 'space-fanatic' Moore family to send the pup beyond the stratosphere. 'He was the best dog, just so soft and nice and loved hugs,' recalled Moore, 60, who lives in Dripping Springs, Texas, just outside Austin. 4 The Moore family can't wait to watch their beloved pooch go galactic. Celestis, Inc Franz, who was 13 when he died in October 2020, was more like a sibling than a pet to Moore's now 26-year-old daughter, Elizabeth, and son, Quinn, 21, he said. Now, the family can't wait to watch the good boy go galactic. 'The emotional power of being with a group of people who are celebrating the life of a loved one in this way … it's amazing. It's nothing we'll ever forget,' said Moore. 'It's just pure joy.' 4 The Perseverance Flight will carry a total of 166 titanium and aluminum capsules, ranging in size from a quarter to a half-inch, filled with DNA or cremated remains. Celestis, Inc 'Many people whose ashes and DNA are flying are people that always wanted to go to space in their lifetime but were never able to do that. It also helps families move from feelings of grief to joy,' Chafer said. The cremated remains of Wesley Dreyer — an aerospace engineer who helped investigate the cause of the Space Shuttle Challenger's shocking explosion after takeoff on Jan. 28, 1986 — will also be on board the Perseverance Flight, as well as DNA from a living, 3-year-old German boy.
Yahoo
8 hours ago
- Yahoo
How Is Hologic's Stock Performance Compared to Other Health Care Equipment Stocks?
With a market cap of $14.3 billion, Hologic, Inc. (HOLX) is a Massachusetts-based medical technology firm, primarily focused on women's health. The company develops, manufactures, and sells a comprehensive suite of solutions, including molecular diagnostics, medical imaging systems, and surgical devices Companies worth $10 billion or more are generally described as 'large-cap stocks,' and Hologic fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical instruments & supplies industry. The company benefits from robust innovation, supported by over 7,000 patents, which fuels its proprietary technologies and product differentiation. Its diagnostics segment, particularly in molecular testing, has shown strong growth, positioning Hologic well in the expanding global healthcare market. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. However, HOLX shares have retreated 24.5% from their 52-week high of $84.67 touched on Aug. 9, 2024. Meanwhile, HOLX stock has surged 3.2% over the past three months, surpassing the SPDR S&P Health Care Equipment ETF's (XHE) 4.8% plunge over the same time frame. HOLX stock has plummeted 11.3% on a YTD basis and 10.5% over the past 52 weeks, compared to XHE's 10.6% dip in 2025 and a 6.3% fall over the past year. The stock has remained consistently below its 200-day moving average since early December last year, but has climbed above its 50-day moving average since late May. On May 27, HOLX shares surged more than 14%, leading S&P 500 gainers, after reports emerged that TPG Inc. (TPG) and Blackstone Inc. (BX) made (and were turned down on) a non-binding ~$16 billion takeover bid, valuing the company at $70–$72 per share. The stock's rally reflected investor optimism and underscored the premium valuation placed on its leadership in women's health and diagnostic capabilities. In the competitive healthcare equipment industry, top rival, Align Technology, Inc.'s (ALGN) 13.7% drop on a YTD basis and 25.7% decline over the past year trails HOLX's losses in the same time frames. Among the 19 analysts covering the HOLX stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $68.27 suggests a 6.7% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
